Sunshine Biopharma
SBFM

Sunshine Biopharma (SBFM) earnings history

Most recent quarter

Period end
Jun 30, 2025
EPS actual
−$3.90
EPS estimate
−$1.10
EPS surprise
−254.55%
Revenue
$9.4M
Reported
Aug 12, 2025

Earnings history

PeriodReportedEPS estimateEPS actualSurpriseRevenueFiling
Q2 2025Aug 12, 2025−$1.10−$3.90−254.55%$9.4MSEC
Q1 2025May 15, 2025$0.00−$4.40+0.00%$8.9MSEC
Q4 2024Apr 1, 2025$0.10−$10.10−10200.00%$9.6MSEC
Q3 2024Nov 5, 2024−$5,350.00−$9.40+99.82%$8.4MSEC
Q2 2024Aug 16, 2024−$6.00−$99.40−1556.67%$9.3MSEC
Q1 2024May 20, 2024−$1,600.00−$400.00+75.00%$7.5MSEC
Q4 2023Mar 28, 2024−$600.00−$1,000.00−66.67%$7.7MSEC
Q3 2023Nov 13, 2023−$1,200.00−$800.00+33.33%$6.0MSEC
Q1 2023May 10, 2023$0.00−$1,600.00+0.00%$4.9MSEC

Quarterly revenue

Q1 2023
$4.9M
Q3 2023
$6.0M
Q4 2023
$7.7M
Q1 2024
$7.5M
Q2 2024
$9.3M
Q3 2024
$8.4M
Q4 2024
$9.6M
Q1 2025
$8.9M
Q2 2025
$9.4M

Frequently asked questions

  • When did Sunshine Biopharma (SBFM) last report earnings?

    Sunshine Biopharma last reported on Aug 12, 2025, covering fiscal Q2 2025.

  • Did SBFM beat earnings estimates?

    No. Sunshine Biopharma reported EPS of −$3.90 for Q2 2025 against a −$1.10 estimate — a 254.55% miss.

  • How much revenue did SBFM report last quarter?

    Sunshine Biopharma reported $9.4M in revenue for Q2 2025, against a consensus estimate of $11.2M.

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.